What Is Procalcitonin? Definition and What Research Reports

Procalcitonin (PCT) is a 116-amino-acid peptide that functions as the biological precursor, or prohormone, of the calcium-regulating hormone calcitonin. Under normal conditions it is produced mainly by the neuroendocrine C cells of the thyroid gland and is rapidly processed into smaller fragments, so very little intact procalcitonin circulates. Reviews of the marker have described how, during systemic bacterial infection and inflammatory states, expression of the precursor rises in many extrathyroidal tissues and intact procalcitonin becomes measurable in serum, which is why it is used clinically and in research as an infection-associated biomarker (PMID 31733680).

What Kind of Molecule Is Procalcitonin?

Procalcitonin belongs to the class of peptide prohormones: relatively long peptide chains that are enzymatically cleaved into shorter, biologically active hormones. In the thyroid, the procalcitonin chain is processed into calcitonin along with other fragments. Educational reviews written for clinicians have summarised this biology and explained that procalcitonin measured in blood is generally interpreted as a marker of the host response rather than as a hormone acting on calcium metabolism (PMID 29343506). Because it is an endogenous peptide with a defined amino-acid sequence, procalcitonin appears in peptide literature alongside other prohormones and precursor peptides, even though it is studied primarily as an analyte rather than as an exogenous agent.

How the Term Is Used in Peptide and Biomarker Research

Three distinct uses of the term appear in the published literature:

• As a diagnostic biomarker. The most common usage. Studies measure serum procalcitonin concentrations and compare them against microbiological or clinical reference standards, an approach summarised in emergency-medicine reviews of sepsis assessment (PMID 33506938).
• As a decision variable in antimicrobial-stewardship research. Trials and meta-analyses have used procalcitonin trajectories as one input into protocols governing when antimicrobials were discontinued in critically ill adults (PMID 38949476).
• As a candidate mediator. A smaller experimental literature treats procalcitonin itself as a bioactive peptide; researchers reported that targeting procalcitonin protected vascular barrier integrity in laboratory models, indicating interest in the peptide as more than a passive marker (PMID 35699655).

Procalcitonin is not an administered research peptide in the way that, for example, synthetic analogues of gut or growth-factor peptides are. In the papers below it is either measured in patient serum or manipulated in preclinical systems.

What the Published Literature Reports

Sepsis and emergency department assessment

A 2020 review in Critical Care Clinics surveyed the accumulated evidence and reported that procalcitonin had been positioned as an adjunct to clinical assessment in suspected bacterial infection rather than a stand-alone test, with performance varying by population and timing of sampling (PMID 31733680). A 2021 update focused specifically on the emergency department described procalcitonin as one of the biomarkers evaluated for early recognition of sepsis in undifferentiated patients (PMID 33506938).

Distinguishing viral from bacterial pneumonia

A systematic review and meta-analysis published in Clinical Infectious Diseases pooled studies that used procalcitonin to separate viral from bacterial pneumonia, and the authors reported that no single threshold performed well enough to be used alone for that distinction (PMID 31241140). That conclusion — reasonable discrimination in aggregate, insufficient accuracy at the individual-patient level — recurs across the diagnostic literature.

Antimicrobial discontinuation research

A 2024 systematic review and network meta-analysis in Critical Care Medicine compared procalcitonin-guided and C-reactive protein-guided strategies for stopping antimicrobials in critically ill adults with sepsis, and the study weighed reported benefits against potential harms of biomarker-guided discontinuation (PMID 38949476). Framing the question as "benefits and harms" reflects the field's recognition that shortening therapy carries trade-offs that a biomarker cannot settle by itself.

Pediatric research

Procalcitonin has been studied extensively in children. A 2025 review in Advances in Pediatrics summarised its role in pediatric emergency medicine, including evaluation of febrile infants and children with suspected serious bacterial infection (PMID 40582754). A separate study examined serum procalcitonin in children with acute meningitis and reported on its value in that specific presentation (PMID 30143413). A 2023 analysis compared procalcitonin levels for identifying bacterial infections in children with and without COVID-19, addressing whether concurrent viral illness altered interpretation (PMID 38633859).

COVID-19-era work

During the SARS-CoV-2 pandemic, researchers re-examined procalcitonin because a marker described as bacteria-associated was being measured in a largely viral epidemic. A 2022 study assessed the diagnostic accuracy of procalcitonin measured on emergency department admission during the pandemic period (PMID 36139922), while a separate paper reviewed proposed pathogenetic mechanisms linking procalcitonin elevation to COVID-19 severity (PMID 34177183).

Beyond infection: vascular biology

Two experimental papers moved procalcitonin from marker to mediator. A 2022 study in Life Sciences reported that procalcitonin mediated vascular dysfunction in obesity models (PMID 35998685), and an American Journal of Respiratory and Critical Care Medicine paper reported that targeting procalcitonin protected vascular barrier integrity (PMID 35699655). These are preclinical mechanistic findings, not clinical outcomes.

Research Contexts at a Glance

Limitations and Harms: What Studies Report

Because procalcitonin is measured rather than administered, the "harms" discussed in the literature are those of misinterpretation and of the management decisions that follow. The 2024 network meta-analysis framed its analysis explicitly around both benefits and harms of biomarker-guided antimicrobial discontinuation in critically ill adults with sepsis (PMID 38949476). Diagnostic-accuracy work has repeatedly reported that thresholds do not transfer cleanly between settings; the pneumonia meta-analysis concluded that procalcitonin alone did not reliably separate viral from bacterial disease (PMID 31241140), and pandemic-era studies re-tested admission accuracy under changed epidemiology (PMID 36139922). Practical guidance written for clinicians has emphasised that the result is interpreted alongside history, examination and other tests (PMID 29343506).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any laboratory test, symptom or treatment decision. Nothing here describes how procalcitonin testing should be ordered or interpreted in an individual case.

References

• Procalcitonin: Where Are We Now? (Critical Care Clinics, 2020)
• Procalcitonin and sepsis in the Emergency Department: an update (European Review for Medical and Pharmacological Sciences, 2021)
• Procalcitonin in Pediatric Emergency Medicine (Advances in Pediatrics, 2025)
• Benefits and Harms of Procalcitonin- or C-Reactive Protein-Guided Antimicrobial Discontinuation in Critically Ill Adults With Sepsis (Critical Care Medicine, 2024)
• How to use… Procalcitonin (Archives of Disease in Childhood: Education and Practice, 2018)
• Procalcitonin to Distinguish Viral From Bacterial Pneumonia: A Systematic Review and Meta-analysis (Clinical Infectious Diseases, 2020)
• Procalcitonin Levels in Identifying Bacterial Infections in Children with and without COVID-19 (Infectious Diseases & Clinical Microbiology, 2023)
• Procalcitonin mediates vascular dysfunction in obesity (Life Sciences, 2022)
• Diagnostic Accuracy of Procalcitonin upon Emergency Department Admission during SARS-CoV-2 Pandemic (Antibiotics, 2022)
• Pathogenetic Mechanism of Procalcitonin in COVID-19 (Indian Journal of Critical Care Medicine, 2021)
• The value of serum procalcitonin in acute meningitis in children (Journal of Clinical Neuroscience, 2018)
• Targeting Procalcitonin Protects Vascular Barrier Integrity (American Journal of Respiratory and Critical Care Medicine, 2022)